Inhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells.
Malotilate (diisopropyl,1,3-dithiol-2-ylidenemalonate, MT) is clinically used as a hepatoprotective agent. Because we noticed that MT induced the differentiation of cultured vascular endothelial cells, we have examined its effects on lung metastasis of the highly metastatic rat mammary carcinoma c-SST-2. MT was orally administered to syngeneic SHR rats from 7 days before or after s.c. inoculation of c-SST-2 cells to the end of the experiments. In the MT-treated rats, pulmonary metastasis was markedly suppressed compared with the non-treated rats. In the rats treated with MT for 19 days after i.v. inoculation of c-SST-2 cells, lung metastasis was also significantly suppressed. An in vitro invasion assay using a rat lung endothelial (RLE) cell monolayer revealed that pretreatment of the RLE cells with MT, but not c-SST-2 cells, significantly reduced the invasion of the RLE monolayer by c-SST-2 cells. An in vitro vascular permeability assay demonstrated that MT prevented the increase in permeability of the RLE monolayer by serum starvation. On the other hand, in vivo and in vitro growth, gelatinase production and adhesion to the RLE cell monolayer of c-SST-2 cells were not affected by MT treatment. These findings suggest that MT suppressed tumour metastasis by intensifying the cell-to-cell contact of endothelial cells, thus preventing tumour cells from invading vascular endothelium.
Nagayasu
H
H
Division of Pathology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan.
Hamada
J
J
Kawano
T
T
Konaka
S
S
Nakata
D
D
Shibata
T
T
Arisue
M
M
Hosokawa
M
M
Takeichi
N
N
Moriuchi
T
T
D000818:Animals; D002277:Carcinoma / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary*; D002448:Cell Adhesion / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002463:Cell Membrane Permeability / Q000187:drug effects; D003094:Collagen; D004338:Drug Combinations; D004354:Drug Screening Assays, Antitumor; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D005260:Female; D018093:Gelatinases / Q000096:biosynthesis / Q000187:drug effects; D007797:Laminin; D008175:Lung Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary*; D008314:Malonates / Q000493:pharmacokinetics / Q000494:pharmacology*; D015674:Mammary Neoplasms, Animal / Q000473:pathology*; D009361:Neoplasm Invasiveness; D011509:Proteoglycans; D051381:Rats; D011918:Rats, Inbred SHR; D014407:Tumor Cells, Cultured / Q000187:drug effects
D004338:Drug Combinations; D007797:Laminin; D008314:Malonates; D011509:Proteoglycans; C059485:matrigel; D003094:Collagen; D018093:Gelatinases; C024808:diisopropyl 1,3-dithiol-2-ylidenemalonate